Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. (Nasdaq: BDSX) is a diagnostic solutions company with a strong focus on lung disease and oncology, and its news flow reflects that specialization. Company updates frequently cover performance of its lung diagnostics business, including revenue trends, test volumes, and reimbursement developments for its Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance.
Investors and clinicians following BDSX news can expect regular financial and operating results releases, where Biodesix reports revenue from Lung Diagnostics and Development Services, discusses gross margins, and comments on measures such as Adjusted EBITDA. These announcements often describe factors influencing growth, such as increased test adoption, payer coverage, and expansion into clinical settings like pulmonology and primary care.
Biodesix also issues news about its Development Services activities and partnerships with biopharmaceutical and life sciences companies. Recent items include an expanded agreement to develop and clinically validate Droplet Digital PCR high complexity assays on Bio-Rad platforms, as well as availability of an ultra-sensitive ESR1 assay for biopharma customers and clinical use in advanced breast cancer.
Another recurring theme in BDSX news is scientific and medical conference participation. The company highlights poster presentations, workshops, and corporate events at meetings focused on lung cancer, breast cancer, pharmacoeconomics, and molecular pathology. These stories showcase new clinical utility data for Nodify Lung tests, health economic analyses of pulmonary nodule management, and research on molecular diagnostic technologies such as NGS, ddPCR, and mass spectrometry.
In addition, Biodesix reports on corporate and capital markets developments, including reverse stock split actions and Nasdaq listing compliance updates, as well as investor conference participation. For users tracking BDSX, this news page provides a centralized view of operational performance, scientific progress, collaborations, and key corporate milestones over time.
Biodesix (NASDAQ: BDSX), a diagnostic solutions company, has announced its participation in two upcoming investor conferences. The company will attend the 22nd Annual Craig-Hallum Institutional Investor Conference for one-on-one meetings on May 28, 2025, in Minneapolis, MN. Additionally, Biodesix will present at the 45th Annual William Blair Growth Stock Conference on June 4, 2025, at 9:20 AM CT in Chicago, IL. The William Blair conference presentation will be available via webcast and can be accessed through the Investors section of Biodesix's website under \"News & Events\".
Biodesix (NASDAQ: BDSX) announced new data presentations for its Nodify Lung® Tests at two major conferences: ISPOR 2025 and ATS 2025. At ISPOR, a study of over 350,000 patients revealed concerning trends in lung nodule management: approximately two-thirds of patients receive no clinical work-up after nodule discovery, 60% of biopsies were performed on benign nodules, and 35% of malignant nodules only received follow-up CT scans before diagnosis.
At ATS 2025, an independent study from Wyckoff Heights Medical Center will present results from 103 patients who received Nodify Lung testing, demonstrating the test's role in lung cancer screening programs and its potential to guide management decisions through actionable results.
Biodesix (NASDAQ: BDSX) has been named a Colorado Top Workplaces 2025 Winner, marking its second consecutive year of workplace excellence recognition. The award, part of an 18-year-old program celebrating people-first organizations, was based on confidential employee feedback collected through Energage's third-party survey. Biodesix was among only 150 companies to receive this recognition.
The diagnostic solutions company's workplace culture was evaluated on various themes, including employee respect, support, growth opportunities, and execution empowerment. This achievement follows their 2024 Inc. Magazine Best Workplaces award, demonstrating consistent excellence in workplace culture. CEO Scott Hutton credited the team members for their role in creating a high-performing workplace culture while serving healthcare customers, patients, and industry partners.
Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.
Key details of the earnings call:
- Financial results cover the quarter ended March 31, 2025
- Management will provide a general business update
- Analysts can participate in Q&A through a dedicated link
- Participants should join 15 minutes before start time
- Webcast replay will be available on investor website approximately two hours after call completion
Biodesix (NASDAQ: BDSX) and Bio-Rad Laboratories have contributed to groundbreaking research findings from Friends of Cancer Research's ctMoniTR Project, published in Clinical Cancer Research. The study demonstrates a strong correlation between circulating tumor DNA (ctDNA) changes and treatment outcomes in cancer patients.
The research expands on previous findings, analyzing multiple solid tumor types and treatment categories, including patients treated with tyrosine kinase inhibitors. The study utilized Bio-Rad's Droplet Digital™ PCR technology to detect ctDNA from patient samples.
Biodesix is currently exploring ctDNA in combination with proteomics to detect molecular residual disease (MRD), with latest advancements to be presented at the upcoming American Association for Cancer Research Annual Meeting on April 28th, 2025.
Biodesix (NASDAQ: BDSX) reported strong financial results for Q4 and FY2024, with total revenue reaching $71.3 million, a 45% increase year-over-year. The company's performance was driven by a 43% growth in Lung Diagnostics revenue to $64.7 million and a 70% increase in Biopharma Services revenue to $6.6 million.
Q4 2024 revenue was $20.4 million, up 39% from the previous year. Gross margins improved to 78% for FY2024, up 5 percentage points from FY2023, primarily due to growth in Lung Diagnostic testing and workflow optimization. The company reported a net loss of $42.9 million for FY2024, an 18% improvement year-over-year.
Looking ahead, Biodesix provided FY2025 revenue guidance of $92-95 million. The company ended 2024 with $26.2 million in cash and cash equivalents, and subsequently amended its term loan facility with Perceptive Advisors to extend the availability of a $10 million Tranche C loan.
Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has announced its participation in the TD Cowen 45th Annual Health Care Conference. CEO Scott Hutton and CFO Robin Cowie will engage in a fireside chat and conduct one-on-one investor meetings on March 5, 2025.
The presentation is scheduled for 1:50 PM ET in Boston, MA. Investors and interested parties can access the live webcast and replay through the 'News & Events' section of the Investors page on biodesix.com.
Biodesix (NASDAQ: BDSX) has scheduled its Q4 and full-year 2024 financial results announcement for March 3, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Management will conduct a question-and-answer session for analysts, and a replay will be available on the company's investor website approximately two hours after the call concludes. Participants are recommended to join 15 minutes before the start time.
Biodesix (NASDAQ: BDSX) reported preliminary, unaudited results for Q4 and full-year 2024, showing significant growth across all segments. Total revenue reached an estimated $71.3 million for 2024, marking a 45% increase year-over-year, with Q4 revenue at $20.4 million, up 39%.
Lung Diagnostics, the company's primary segment, generated estimated revenue of $64.7 million for 2024 (up 43%) and $17.2 million for Q4 (up 34%), with test volumes reaching 54,300 for the year. Biopharma Services showed strong growth with $6.6 million in 2024 revenue (up 69%) and enters 2025 with $12.2 million under contract.
The company ended 2024 with cash and cash equivalents of $26.2 million, having focused on operational efficiencies and cost discipline throughout the year while expanding commercial, clinical, and R&D capabilities.